Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
WELLBUTRIN is an oral small-molecule antidepressant approved in 1985, currently approaching loss of exclusivity. The drug's mechanism of action and specific indications are not detailed in available data, but it remains a foundational treatment in mental health therapeutics.
As LOE approaches, the WELLBUTRIN brand team will transition from growth-focused work to lifecycle management and potential generic defense strategies, likely resulting in smaller commercial teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks
Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features
A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects
A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure
Wellbutrin XL, Major Depressive Disorder and Breast Cancer
Worked on WELLBUTRIN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on WELLBUTRIN in its LOE phase offers limited career growth but provides valuable experience in lifecycle management, generic defense, and transition planning. Professionals should consider this a consolidation role before moving to growth-stage assets.